Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Fibrogen Inc CS (FGEN)
Fibrogen Inc CS (FGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,883,660
  • Shares Outstanding, K 94,183
  • Annual Sales, $ 140,730 K
  • Annual Income, $ -293,650 K
  • 60-Month Beta 0.85
  • Price/Sales 13.38
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade FGEN with:

Options Overview Details

View History
  • Implied Volatility 81.26% ( +16.85%)
  • Historical Volatility 24.11%
  • IV Percentile 88%
  • IV Rank 50.98%
  • IV High 104.60% on 05/31/22
  • IV Low 56.98% on 06/14/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 204
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 25,342
  • Open Int (30-Day) 37,247

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.76
  • Number of Estimates 5
  • High Estimate -0.64
  • Low Estimate -0.89
  • Prior Year -0.68
  • Growth Rate Est. (year over year) -11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.46 +3.34%
on 03/15/23
23.53 -14.53%
on 02/28/23
-2.49 (-11.02%)
since 02/21/23
3-Month
15.18 +32.48%
on 12/27/22
25.69 -21.72%
on 02/03/23
+4.36 (+27.68%)
since 12/21/22
52-Week
7.81 +157.49%
on 05/09/22
25.69 -21.72%
on 02/03/23
+7.21 (+55.89%)
since 03/21/22

Most Recent Stories

More News
Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?

Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.

FGEN : 20.00 (-0.20%)
ASRT : 5.97 (+3.29%)
ALVR : 4.77 (+4.84%)
TCRT : 0.4700 (+3.30%)
FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 20.00 (-0.20%)
ASRT : 5.97 (+3.29%)
FibroGen: Q4 Earnings Snapshot

FibroGen: Q4 Earnings Snapshot

FGEN : 20.00 (-0.20%)
Should You Buy FibroGen (FGEN) Ahead of Earnings?

FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FGEN : 20.00 (-0.20%)
4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates

We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.

CYTK : 35.37 (+0.48%)
TBPH : 10.55 (+1.05%)
FGEN : 20.00 (-0.20%)
AUPH : 9.34 (+1.30%)
Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IMGN : 4.00 (+1.78%)
FGEN : 20.00 (-0.20%)
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FGEN : 20.00 (-0.20%)
XNCR : 28.90 (+0.59%)
Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?

Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.

ARDX : 4.03 (+3.87%)
FGEN : 20.00 (-0.20%)
ASRT : 5.97 (+3.29%)
EQRX : 1.9300 (+3.76%)
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are expected to have driven sales, partially offset by lower sales of livestock, cattle, poultry and...

ZTS : 166.39 (+0.34%)
FGEN : 20.00 (-0.20%)
ASRT : 5.97 (+3.29%)
EQRX : 1.9300 (+3.76%)
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

AZN : 66.57 (-0.25%)
GSK : 34.98 (+0.14%)
AKBA : 0.6900 (+1.94%)
FGEN : 20.00 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

3rd Resistance Point 20.55
2nd Resistance Point 20.32
1st Resistance Point 20.16
Last Price 20.00
1st Support Level 19.78
2nd Support Level 19.55
3rd Support Level 19.39

See More

52-Week High 25.69
Last Price 20.00
Fibonacci 61.8% 18.86
Fibonacci 50% 16.75
Fibonacci 38.2% 14.64
52-Week Low 7.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar